investigator-initiated trials

In high-pressure therapeutic areas such as oncology, a new model for investigator initiated trials (IITs) is becoming more popular among pharmaceutical companies. Rather than going through an in-house medical grants process to fund IITs, some companies are joining...

As the old saying goes, "Good help is hard to find." Well, sometimes the best option is to make it easier for the help to find you. Our research has shown that Investigator-Initiated Trial proposals are on the rise over the last three years — averaging 173.3...

By David Richardson, Research Team Leader The Office of the Inspector General at Health and Human Services (OIG) has been highly focused recently on tracking and publicizing pharmaceutical companies' payments to thought leader physicians and clinical...

By Ryan McGuire, Senior Research Analyst Pharmaceutical companies are growing more strategic in their investigator initiated trial (IIT) selection. As Research and Development organizations have sharpened their focus on mission-critical pre-approval...

Our current review of pharmaceutical and biotechnology strategy for the new year finds that 42 percent of companies will be increasing their budgets for investigator initiated trials. Companies fund investigator initiate trials (IITs) to support additional clinical...

Over Half of Drug Companies Now Use Electronic or Web-Based Tools for Managing Proposals Electronic or web-based submission systems for investigator initiated trial (IIT) proposals are now in place at 58% of biopharmaceutical companies, and that number is expected...

While sponsors maintain editorial distance from investigators' findings, they increasingly push researchers to take action on publication Published data from investigator-initiated trials (IIT) have proven extremely valuable for both scientific and commercial...

Investigator initiated trial (IIT) management teams must incorporate fair-market value (FMV) into their payment protocols to appropriately respond to regulatory scrutiny and maintain compliance. In our new study, "Investigator Initiated Trial Management," 23 percent...

Blockbuster brands' IIT spending booms with large companies topping $20 million Pharmaceutical and biotech companies increased their investigator initiated trial (IIT) budgets by an average 21 percent this year, and they're not stopping there. Our newest study,...

Phase IV trials serve an increasingly important role in the commercialization of pharmaceutical products. They serve a range of purposes, from augmenting safety, tolerability and real-time effectiveness data and identifying potential new indications to developing...